This article explores the potential of the novel antidepressant dextromethorphan-bupropion in addressing treatment-resistant depression (TRD). Traditional approaches, including selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors, alongside antipsychotic agents, often prove insufficient. Amid a global surge in TRD post-COVID-19, dextromethorphan-bupropion...